TC Biopharm () (TCBPW)
0.01
-0.00 (-32.43%)
At close: Mar 03, 2025, 3:57 PM
Company Description
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform.
Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm ()
| Country | GB |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Bryan Leland Kobel |
Contact Details
Address: Maxim 1 Motherwell, GB | |
| Website | https://www.tcbiopharm.com |
Stock Details
| Ticker Symbol | TCBPW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001872812 |
| CUSIP Number | 87807D111 |
| ISIN Number | US87807D1110 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bryan Leland Kobel | Chief Executive Officer & Director |
| Martin Edward Thorp | Chief Financial Officer & Director |
| Christopher Camarra | Executive Vice President of Communications |
| Dr. Lauren Bor Ph.D. | Head of Commercial Development Division |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 10, 2025 | 6-K | Filing |
| Jan 08, 2025 | 6-K | Filing |
| Jan 08, 2025 | 6-K | Filing |
| Dec 31, 2024 | 6-K | Filing |
| Dec 30, 2024 | 6-K | Filing |
| Dec 17, 2024 | 6-K | Filing |
| Dec 16, 2024 | 424B5 | Filing |
| Dec 16, 2024 | 6-K | Filing |
| Nov 27, 2024 | F-3 | Filing |
| Nov 25, 2024 | 6-K | Filing |